3.39MMarket Cap-59P/E (TTM)
0.1900High0.1600Low662.83KVolume0.1900Open0.1900Pre Close118.14KTurnover4.56%Turnover RatioLossP/E (Static)19.52MShares2.907752wk High-0.37P/B2.52MFloat Cap0.130052wk Low--Dividend TTM14.54MShs Float1457.9988Historical High--Div YieldTTM15.79%Amplitude0.1300Historical Low0.1780Avg Price1Lot Size
Aptose Biosciences Stock Forum
so far so guuud
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
2 minutes ago, 4:30 AM PST
Via GlobeNewswire
APTO
Share
• TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites
• Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populations
• Study execution update is ...
patience needed here.
No comment yet